-
Previous Post
Introducing the Accretiv team!
At Accretiv, we firmly believe that individual aspirations and community well-being go hand in hand. As a dedicated investor in the healthcare sector, we recognize the essential role that nurses play in delivering quality patient care. To address the growing nursing shortage, we are actively supporting the next generation of medical professionals through the Accretiv Nursing Scholarship Program.
The U.S. healthcare system faces a significant shortfall in nursing professionals. According to a report by Mercer, by 2028, the country is expected to experience a deficit of 73,000 nursing assistants, exacerbated by an aging population and increasing demand for healthcare services. StatPearls highlights key challenges, including a shortage of nursing educators, high turnover rates, and an aging workforce, with more than 50% of registered nurses over the age of 50.
The Bureau of Labor Statistics (BLS) projects that there will be 193,100 job openings for registered nurses (RNs) each year through 2032, largely due to retirements and increased demand for healthcare services. Furthermore, the Health Resources & Services Administration (HRSA) projects that by 2037, an additional 159,310 Licensed Practical Nurses (LPNs) will be needed to meet the growing healthcare demands of an aging population.
Nurses represent the largest segment of the healthcare workforce, providing critical services such as direct patient care, chronic disease management, and public health education. However, despite their essential role, many aspiring nurses face significant financial barriers to entering the profession.
Recognizing these challenges, Accretiv is committed to empowering future healthcare professionals by providing financial assistance through the Accretiv Nursing Scholarship Program, working together with Gateway Community Colleges. This initiative is designed to support nursing students as they pursue their education, alleviating financial stress and ensuring a steady pipeline of skilled professionals in the healthcare system.
"When you’re incapacitated by illness, good nursing care can make all the difference to your comfort and speedy recovery," says Accretiv COO and co-founder Justin Clarke, who is himself a paraplegic and acutely aware of the importance of great nursing. "I can attest to the importance of this vital part of patient care. Nurses kept me alive, got me motivated, and rehabilitated into society, putting me in a position where I can now pay that forward. That’s why we are committed to supporting the education and training of future nurses."
The total cost of a four-year Bachelor of Science in Nursing (BSN) program typically ranges from $40,000 to $120,000, depending on the institution. Financial pressures are a leading cause of student attrition, with the National League for Nursing reporting that one in five nursing students drops out primarily due to economic constraints.
Through the Accretiv Nursing Scholarship Program, we help students cover tuition costs, allowing them to focus on developing critical skills in leadership, patient care, and public health. This funding supports individuals pursuing careers as Certified Nursing Assistants (CNAs), Registered Nurses (RNs), and Nurse Practitioners (NPs)—all of whom play a vital role in improving healthcare access and quality nationwide.
At Accretiv, we recognize that our business extends beyond investments in healthcare infrastructure. By directly contributing to the education of nurses, we are investing in the long-term stability of the U.S. healthcare system.
Our commitment to supporting nursing education is rooted in our belief that a well-trained and well-supported workforce is essential to the health and well-being of our communities. Through the Accretiv Nursing Scholarship Program, we are working to ensure that aspiring nurses have the resources they need to succeed, ultimately strengthening the future of healthcare in America.
Previous Post
We’re a small, tight-knit team with a goal to create a community of everyday investors…
AccretivUSA Inc. (the “Company”) is conducting an offering pursuant to Regulation A under the Securities Act of 1933, as amended (the “Securities Act”). Regulation A offerings allow the Company to offer and sell securities to both accredited and non-accredited investors, subject to certain investment limits and compliance requirements. This offering is being conducted under Tier 2 of Regulation A, which permits investments from the general public subject to limits on the amount non-accredited investors can invest.
The Company has filed an offering circular with the Securities and Exchange Commission (the “SEC”), which has been qualified and is available for review on the SEC’s EDGAR database and the Company’s website here.
Investors are encouraged to carefully read the offering circular in its entirety, including the “Risk Factors” section, for detailed information about the Company, the securities offered, and the associated risks.The offering is subject to investment limits as set forth under Regulation A:
• Non-accredited investors may invest no more than 10% of their annual income or net worth, whichever is greater.
• Accredited investors are not subject to these investment limits.
Investors should only make investment decisions after reviewing the offering circular and conducting their own due diligence. The offering circular contains key information about the Company’s business, operations, financial condition, and other important details.Dalmore Group, LLC (“Dalmore”) is a registered broker-dealer and member FINRA/SIPC. Dalmore acts solely as the broker-dealer of record for the Company’s Regulation A offering, facilitating back-office and regulatory functions. Dalmore does not provide investment advice or recommendations and is not affiliated with the Company. Accretiv and Dalmore are not affiliates.
Investing in the Company’s securities involves substantial risks, including the risk of losing your entire investment. Securities offered under Regulation A are speculative, illiquid, and may not provide a return on investment. Past performance is not indicative of future results. Investors should review the “Risk Factors” section of the offering circular for a full discussion of risks.
Investors will need to provide certain information to confirm their eligibility to invest in the offering, including their income or net worth, as required under Regulation A.
The Company may use this information to determine compliance with the applicable investment limits.Investors holding Preferred Shares are entitled to an 8% APY return, which is accumulated and compounded over the investment period but will not be distributed until the final withdrawal of funds or a qualifying liquidity event and will only be distributed at the discretion of the Company. For the purposes of this offering, a liquidity event is defined solely as the sale of a property owned by the company. Investors must maintain their investment for a minimum holding period of 48 months before requesting a withdrawal.
Early withdrawals are subject to a 5% fee and are limited to an annual withdrawal cap of 5% of the fund’s total value. Exceptions may be granted for special circumstances, including death, disability, or bankruptcy; however, these cases remain subject to the annual withdrawal limit. There is no guarantee that a liquidity event will occur, and returns are subject to the company’s financial performance.
Investors should carefully review all offering materials and consult with a financial advisor before investing.
The materials and communications provided by the Company are based on its internal estimates, which are subject to change. While the Company has made reasonable efforts to ensure the accuracy of the information, it is not guaranteed, and no representation or warranty, express or implied, is made regarding the fairness, completeness, or reliability of the information provided. Investors are advised to consult with their financial, legal, and tax advisors before making any investment decisions.
The Company’s materials may contain forward-looking statements regarding its business, operations, and future performance. These statements are based on the Company’s current expectations and assumptions and are subject to risks and uncertainties that may cause actual results to differ materially. For a detailed discussion of these risks, refer to the “Risk Factors” section of the offering circular.
The Company’s securities offered under Regulation A are subject to limitations on resale under applicable securities laws. The Company makes no assurance of liquidity or a secondary market for its securities.